Reclassification under the WHO 2022 criteria would correspond to a Grade 1 neuroendocrine tumor (well-differentiated, 0 mitoses per 2 mm2, and a Ki67 proliferation index of 1%). Here, MKI67 is linked to neuroendocrine neoplasm.